Journavx (Suzetrigine): A Non-Opioid Option for Pain
What Is Journavx?
Journavx (generic name: suzetrigine) is a prescription oral medication for the treatment of moderate-to-severe acute pain in adults, including pain following surgery. It is a new class of non-opioid analgesics called NaV1.8 sodium channel blockers.
For patients recovering from orthopedic or sports medicine procedures, Journavx offers a way to manage post-surgical pain without the side effects of opioid medications.
How It Works: Mechanism of Action
Pain signals travel from an injury site to the brain along peripheral sensory neurons. These neurons rely on voltage-gated sodium channels to generate the electrical impulses that carry pain signals to the brain. One of these channels, called NaV1.8, is found almost exclusively in peripheral pain-sensing neurons and plays a central role in initiating and propagating signals.
Suzetrigine is a highly selective NaV1.8 blocker. By binding to this channel, it prevents the peripheral neuron from firing, essentially blocking the pain signal at its source, before it ever reaches the central nervous system.
This is a fundamentally different strategy from how opioids work. Opioids act on mu-opioid receptors in the brain, which does relieve pain, but also produces the sedation, euphoria, and reward-pathway activation that underlie opioid tolerance, dependence, and addiction. NaV1.8 channels are concentrated in the peripheral nervous system ONLY rather than the brain, thus suzetrigine can block pain transmission without engaging the brain's reward circuit.
Why Dr. Black Prefers Journavx Over Opioids
No addiction potential: Suzetrigine does not bind opioid receptors and does not increase dopamine signaling in the brain's reward pathway. As it does not produce that reward signal, it has no risk of abuse or dependence like opioids. It is not a controlled substance.
No respiratory depression risk. Opioid overdose is dangerous primarily because opioids suppress the brainstem's drive to breathe. Suzetrigine does not act at the brain level, thus this risk is not a concern with Journavx.
Clinically comparable pain relief in trials. In the pivotal Phase 3 trials that supported FDA approval, patients recovering from surgery who took suzetrigine reported less pain than those on placebo, with a reduction in pain intensity similar to that seen with hydrocodone/acetaminophen, a commonly prescribed opioid combination.
Favorable side-effect profile. Journavx does not cause the sedation, mental fog, constipation, or itching commonly associated with opioid therapy. The most commonly reported side effects are muscle spasms, elevated creatine kinase, and rash.
No withdrawal on discontinuation. Journavx does not produce the withdrawal symptoms associated with stopping opioids.
Who Should Not Use Journavx
Journavx isn't appropriate for everyone. Patients should not take it, or should use it only with caution and physician guidance, in the following situations:
Hormonal contraceptive users. Suzetrigine can reduce the effectiveness of hormonal birth control. Patients relying on hormonal contraception should use a backup method during treatment and for 28 days after stopping Journavx.
Severe liver impairment. Journavx is contraindicated in patients with severe hepatic impairment, since the liver is responsible for metabolizing the drug.
Concurrent use of CYP3A4 inhibitors. Journavx is broken down by the liver enzyme CYP3A4. Taking it alongside CYP3A4 inhibitors (antifungals (itraconazole or ketoconazole), some HIV medications, clarithromycin, rifampin, St John’s Wort, grapefruit) is contraindicated because it significantly raises drug levels and the risk of side effects. Patients should disclose their full medication list to their prescriber.
Pregnancy, breastfeeding, and pediatric use. Safety and effectiveness have not been established in pregnant or breastfeeding patients or in patients under 18; use in these populations should only occur under direct physician guidance.
As with any new medication, patients should give their full medical and medication history to their surgeon or prescriber before starting Journavx.
Frequently Asked Questions
Is Journavx an opioid? No. It works through an entirely different mechanism, blocking a sodium channel in peripheral nerves, and it is not a controlled substance.
How is it taken? Journavx is a 50mg oral tablet. The typical regimen is a 100 mg loading dose (2 tables) the evening before or the morning of surgery, followed by 50 mg every 12 hours. It should be taken on an empty stomach, at least one hour before or two hours after eating, since food can delay how quickly it starts working.
How quickly does it work? In clinical trials, patients experienced meaningful pain relief within a few hours of the first dose.
Can Journavx be used in conjunction with OrthoLazer Therapy? Yes. Both treatments work through different mechanisms and can have a synergist effect when used together.
Can it be used for chronic pain, like arthritis? Not currently. Journavx is FDA-approved only for moderate-to-severe acute pain, such as pain following surgery or injury. Its safety and efficacy for chronic pain conditions have not yet been established.
Can it be combined with other pain medications? In some cases, yes; Journavx may be used as part of a multimodal pain plan alongside acetaminophen, NSAIDs, or, when needed, a limited course of opioids.
Is it covered by insurance? Coverage varies by insurer and plan. Savings programs are available for this medication at can be found at this website.
What are the most common side effects? The most frequently reported side effects in clinical trials were mild and included itching, muscle spasms, and elevated creatine kinase. Serious side effects were uncommon.
Why hasn't my doctor prescribed this before? Journavx only received FDA approval in January 2025, so it's still a relatively new option. Many surgeons, including this practice, are incorporating it into post-operative pain protocols as part of a broader effort to reduce reliance on opioids after surgery.